Neurovalens raises £6M for non-invasive neurostimulation wearable devices
Summary
Neurovalens has closed a £6 million investment round led by the Investment Fund for Northern Ireland, with participation from Whiterock, IQ Capital, Innovation Ulster, and the Angel Co-Fund. The Belfast-based company develops wearable medical devices that deliver non-invasive electrical stimulation to treat anxiety, insomnia, and PTSD. The funding will support commercial expansion in the US and global markets.
Why it matters
Neurovalens has received FDA clearance for its Modius Stress device for treating generalized anxiety disorder, one of the first non-invasive neurostimulation devices to achieve this milestone. The company has raised approximately £20 million in total and is preparing for a $40-50 million Series B, positioning it as a leader in wearable neurostimulation for mental health.
Want the full NeurotechMag Pro intelligence database?
Access 800+ papers, trials, patents, funding rounds and news items — updated daily.
Start free trial